Banzel Mobile Logo A Challenging Form of Epilepsy Seizure Types in LGS LGS Patient Profiles Pivotal Trial Design Efficacy of BANZEL® in Seizure Reduction Seizure Severity Rating Responder Rates Adverse Reactions Mechanism of Action/Pharmacokinetics Dosing

BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Prescribing Information Important Safety Information For Patients

LGS PATIENTS EXPERIENCE MULTIPLE SEIZURE TYPES

Seizure types characteristic of LGS may include1,2

Tonic-atonic (drop attacks)
Atypical absence
Tonic
Atonic
Myoclonic
Tonic-clonic
Partial
Absence
Clonic
  • References: 1. Markand. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol. 2003;20(6):426-441. 2. Campos-Costello. Lennox-Gastaut syndrome. Orphanet Encyclopedia. http://www.orpha.net/data/patho/GB/uk-Lennox.pdf. Published 2003. Updated 2004. Accessed October 10, 2013.
◄Previous Next: LGS PATIENT PROFILES►
Efficacy icon

EFFICACY ►

Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial